etanercept   

GtoPdb Ligand ID: 6789

Synonyms: Enbrel® | Rhu Tnfr:Fc | TNFR-Fc | TNR 001
etanercept is an approved drug (FDA (1998), EMA (2000))
Compound class: Antibody
Comment: Etanercept is a TNFα inhibitor. It is a dimeric recombinant protein fusing the TNF receptor 2 (TNFRSF1B) to the Fc region of the human IgG1 antibody. Etanercept is used as a disease-modifying anti-rheumatic drug (DMARD).

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
etanercept-szzsErelziSandozApproved (2016 FDA, 2017 EMA)As per reference agent 
SB4; etanercept-ykroBrenzys; Benepali; Eticovo Samsung BioepisApproved in S Korea (2015), Canada (2016), Europe (EMA 2016), US (FDA 2019) and othersAs per reference agent[1]
 LifmiorPfizerApproved (2017 EMA)As per reference agent 
ENIA11; TuNEX; OpinerceptMycenax BiotechApproved (2018 Taiwan)Rheumatoid arthritisReuters news brief
EtaceptReumatoceptShanghai CP GoujianMarketed in Colombia as Etanar Rheumatoid arthritis 
CHS-0214 Coherus BiosciencesPh 3 (NCT02134210)Plaque psoriasis 
LBEC0101 LG Life SciencesPh 3 (NCT02357069)Rheumatoid arthritis[4-5]
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: etanercept

No information available.
Summary of Clinical Use
Used to treat severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.
Mechanism Of Action and Pharmacodynamic Effects
Etanercept acts as a TNF inhibitor, by immuno-neutralising circulating TNF.
External links